The following disclosures are a reflection of what has been reported to SHEA. To provide thorough transparency, SHEA requires full disclosure of all relationships, regardless of relevancy to the guideline topic. Such relationships as potential conflicts of interest are evaluated in a review process that includes assessment by the SHEA Conflict of Interest Committee and may include the Board of Trustees and Editor of Infection Control and Hospital Epidemiology. The assessment of disclosed relationships for possible conflicts of interest has been based on the relative weight of the financial relationship (i.e., monetary amount) and the relevance of the relationship (i.e., the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). All other authors report no conflicts of interest related to this article. SDA reports grants from the SHEA Research Scholar Award, NIH and National Institute of Diabetes and Digestive and Kidney Diseases (no. K12DK100024 Career Development Award), CDC (grant nos. 5U54CK000616-02 and SHEPheRD 75D30121D12733-D5-E003), and NIA P30AG028716/Pepper Center, consulting fees from IDSA, BioMerieux, GSK, Locus Biosciences, and Sysmex America for IPEC Experts (co-owner) outside the submitted work. SDA became an employee of GSK/ViiV Healthcare after acceptance of this manuscript. WBE reports grants from Gilead Sciences, personal fees from DLA Piper, LLC and from Medtronic, grants from VA Health Services Research and Development Service (no. IIR 20-076, IIR 20-101), grants from NIH National Heart Lung and Blood Institute outside the submitted work, and is an unpaid scientific advisor to the Massachusetts Department of Elementary and Secondary Education. SG reports holding patents pending to UC Regents for SAFER Lines Mobile App and CLISA Score. KC reports grants from CDC (no. U54CK000610-03; SHEPheRD Contract 200-2016-91796), AHRQ (no. K12HS026393), conference travel support for IDWeek and SHEA Spring 2022, and membership in the SCCM Pediatric Sepsis Definitions Taskforce and the Multiprofessional Society Sepsis Taskforce. SLK reports a grant from the Department of Veterans Affairs (HSR&D Research Career Scientist Award (RCS 11-222)). SCK reports grants from AHRQ (no. R01 HS027819, HHSP2332015000201), CDC (no. U54CK000617-01-00), royalties from McGraw Hill, consulting fees for Pfizer, and payment for expert testimony from Mesh Besher, and serves on the SHEA Research Network Leadership Team. RM has received royalties from UpToDate, Inc. ESS reports consulting fees from Prime Education LLC and participation in the Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (GOAT). GDW reports a grant from Allergan to the Albert Einstein College of Medicine. LLM reports research support from NIA (K24AG050685, P30AG024824), Department of Veterans Affairs (CSR&D Merit Review I01CX001691) and D. Dan and Betty Kahn Foundation outside of this work.